Table 1 Clinical and molecular characteristics of eosinophilic vacuolated tumor (EVT) of kidney in the published studies.

Study	No. of patients	Mean age, (range) years	Male/ Female	No. of EVT tumors	Median size, (range) cm	Multiple tumors	Pre-existing syndromes	Molecular/genetic analysis	Follow-up
He et al.	14	49 (25–73)	3/11	14	3 (1.5–7.0)	0	0	Loss of chr. 1 and 19 (p/q)	ANED
Chen et al.	7	54 (48–68)	3/4	7	3.4 (1.5–5.0)	0	0	Loss of chr. 1, MTOR, TSC2 mutations	ANED
Trpkov et al.	1	48	0/1	1	1.3	AML^a	TSC	NA	ANED
Farcas et al.	19	47 (15–72)	8/11	19	4.3 (1.5–11.5)	0	0	TSC1, TSC2, MTOR mutations	ANED
Kapur et al.	1	55	1/0	1	1.8	0	0	MTOR mutations	ANED
Lerma et al.	1	49	1/0	1	1.8	6^b	TSC^b	TSC1 mutations	ANED
Gupta et al.	1	41	1/0	1	2.2	2^c	TSC	TSC2 mutation (germline)	ANED

Abbreviations: ANED: Alive, no evidence of disease; TSC: Tuberous sclerosis complex; AML: Angiomyolipoma; NA: Not available; Chr.: chromosome
^aMultiple small AMLs (tumorlets) in the renal parenchyma.
^bEosinophilic solid and cystic RCC (x2), low-grade oncocytic tumor (LOT) (x3), and numerus small AMLs, considered “silent TSC”.
^cOne additional “TSC-associated oncocytic tumor” (1.9 cm), with morphologic similarity to LOT (information provided courtesy Dr. Sounak Gupta, Mayo Clinic).

Quick links

Search